TTP plc enters into exclusive licence agreement with DiaSorin to commercialise molecular diagnostics platformMarch 2, 20
- TTP’s Puckdx platform offers a flexible and low-cost solution for translating sample-to-answer assays to a simple, easy-to-use desktop device for a range of diagnostic applications in human and animal health
- DiaSorin will utilise TTP’s Puckdx platform for human in vitro diagnostic assays
Cambridge, UK, and Saluggia, Italy, 02 March 2020: TTP plc (TTP), a leading independent technology and product development company, and DiaSorin, a global leader in the in vitro diagnostic (IVD) field, have signed an exclusive licence and technology transfer agreement. DiaSorin will combine its extensive molecular test offering with TTP’s Puckdx™ platform to develop a single-use, sample-to-answer, molecular diagnostics point-of-care platform for human IVD applications.
TTP’s proprietary Puckdx platform offers a flexible, fast time-to-result and low-cost solution for translating diagnostic assays for human and animal health and life science research to an easy-to-use desktop device. TTP’s Puckdx is based on a unique disposable robotic pipette system with a fast PCR module, combined with a cartridge containing all the necessary reagents.
Using this simple and cost-effective technology solution in combination with DiaSorin’s human IVD assays could provide clients with a result in less than 15 minutes. This could help to decentralise testing, which in turn could make diagnostic services more affordable and convenient for patients and reduce the time from diagnosis to treatment to help prevent the spread of infectious diseases.
Giles Sanders, Consultant at TTP plc said: “Giles Sanders, Consultant at TTP plc, said: “We are delighted that DiaSorin has chosen Puckdx as their preferred POC platform. We look forward to working in close partnership with DiaSorin to rapidly commercialise the platform, benefiting patients and healthcare providers worldwide.”
Piers Harding, Consultant at TTP plc added: “During the development of the Puckdx platform we have focussed on a system that enables easy transfer of assays and a reliable and readily manufactured disposable. We are excited to have such a major diagnostic company wishing to bring the platform to market for human applications. The opportunity to utilise Puckdx for other fields of application continues to be available and we would be keen to collaborate with key players developing assays in areas such as for animal health and low-cost lab robotics”.
TTP’s Puckdx platform is based on a unique disposable robotic pipette system with a fast PCR module, combined with easy-to-use cartridge containing all the necessary reagents. For further information about TTP’s Puckdx platform, please visit: https://www.ttp.com/desktop-biology
This entry was posted in News from Zyme and the companies we work with. Bookmark the permalink.